Aprecia, the 3DP Pharmaceutical Company, has named Kathi Rinesmith, R Ph, MS as its new Senior Vice President of Regulatory Affairs, it was reported on Wednesday.
Rinesmith will head the firm's regulatory strategy, objectives, policies, and programmes for the development and marketing of drug products manufactured with ZipDose Technology, the company's three-dimensional printing technology platform.
Rinesmith has over thirty years of pharmaceutical experience. Most recently, Rinesmith held the position of Director of Global Regulatory Affairs and Global Pharmacovigilance at Adare Pharmaceuticals. He has regulatory and pharmacovigilance experience in commercialised Rx, OTC, and dietary supplement products, and has served as senior executive product development and regulatory roles at Camargo Pharmaceutical Services, Prasco Laboratories, Barr Labs, and Duramed Pharmaceuticals.
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer